Table 1.
Patient characteristics and adverse events
| Dose (µg/peptide) |
Patient (#) |
Gender (F/M) |
Diagnosis | Tumor stage (prevaccination) |
Last Rx | Postvac 1 | Postvac 2 | Postvac 3 | Latest follow-up | Follow-up period (months) |
| 1 | 1 | F | OPSCC | cT2N2bM0 | CRT | – | – | – | NED | 80 |
| 2 | M | OPSCC | cT3N0M0 | CRT | – | – | – | NED | 57 | |
| 3 | M | OPSCC | T2N1M0 | RTx | – | – | – | NED | 56 | |
| 4 | M | OPSCC | cT2N2bM0 | RTx | – | – | – | NED | 58 | |
| 5 | M | OPSCC | cT2pN2b | CRT | – | – | – | NED | 59 | |
| 6 | M | OPSCC | cT1pN1M0 | RTx | – | – | – | NED | 56 | |
| 5 | 7 | M | OPSCC | T2N2cM0 | CRT | VC gr 1 | VC gr 1 | VC gr 1 | NED | 60 |
| 8 | M | OPSCC | cT2N2bM0 | OKD+RTx | – | VC gr 1 | – | NED | 51 | |
| 9 | F | µVIN/HSIL | Laser | VC gr 1 | FLS gr 1+VC gr 1 | VC gr 1 | Recurrence µVIN | 4 | ||
| 10 | F | µVIN/HSIL | – | – | – | – | no response during trial on existing lesions | – | ||
| 11 | F | µVIN/HSIL | Excision | – | – | – | NED | 25 | ||
| 12 | F | VAIN/HSIL | Laser | – | – | – | no response during trial on existing lesions | – | ||
| 20 | 13 | F | CIN2/3 | Re-LETZ | VC gr 1 | VC gr 1 | VC gr 1 | Uterus extirpation PA: CIN 2&3 | 16 | |
| 14 | M | OPSCC | cT2N2M0 | CRT | VC gr 1 | VC gr 1 | VC gr 1 | NED | 24 | |
| 15 | F | CIN3 | LETZ | – | VC gr 1 | VC gr 1 | NED | 42 | ||
| 16 | M | OPSCC | cT3N2bM0 | CRT | VC gr 1 | VC gr 1 | VC gr 1 | NED | 43 | |
| 17 | F | CIN2/3 | – | VC gr 2 | VC gr 2 | VC gr 1 | NED | 6 | ||
| 18 | M | ASCC | cT3N1M0 | CRT | – | – | – | NED | 36 | |
| 50 | 19 | F | LSIL | – | FLS gr 1+VC gr 1 | VC gr 1 | VC gr 1 | Recurrence HSIL | 26 | |
| 20 | F | OPSCC | cT2N0M0 | Rtx | FLS gr 1+VC gr 1 | FLS gr 1+VC gr 1 | VC gr 1 | NED | 38 | |
| 21 | F | ASCC | cT2N1M0 | CRT | VC gr 1 | VC gr 1 | VC gr 1 | Recurrence | 14 | |
| 22 | F | CxCa | cT2bN1M0, FIGO IIB | CRT+brachy | VC gr 1 | VC gr 1 | VC gr 1 | NED | 40 | |
| 23* | F | ASCC | cT3N0M0 | CRT | VC gr 1 | VC gr 2 | NP | NED | 23 | |
| 24 | M | OPSCC | pT1N0M0 | Resection | VC gr 1 | VC gr 2 | FLS gr 1+VC gr 2 | NED | 20 | |
| 25 | F | CIN3 | Cone biopsy | VC gr 1 | VC gr 2 | VC gr 1 | NED | 24 |
*Patient #23 received only two vaccinations.
ASCC, anal squamous cell carcinoma; CIN, cervical intraepithelial neoplasia; CRT, chemoradiotherapy; CxCa, cervical cancer; FLS, flu-like symptoms; Gr, grade; HSIL, high grade squamous intraepithelial lesion; LETZ, Loop Excision of the Transformation Zone; LSIL, low grade squamous intraepithelial lesion; NED, no evidence of disease; NP, not performed; OPSCC, oropharyngeal squamous cell carcinoma; Rtx, radiotherapy; Rx, treatment; uVIN, usual vulvar intraepithelial neoplasia; VAIN, vaginal intraepithelial neoplasia; VC, vaccination complication.